Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Price

ADPTStock

$26.25+96.54%52W

Market Cap$4.19B

P/E—

PEG Ratio—

Div yield—

Beta2.13

ADPT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)49.75%

Price vs S&P 500 (4W)10.40%

VGM Score62.30

Book Value / Share (Quarterly)$0.90

P/TBV (Annual)11.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.34%

Cash Flow / Share (Quarterly)$-0.15

Price vs S&P 500 (YTD)45.37%

Gross Margin (TTM)75.57%

Net Profit Margin (TTM)-20.73%

EPS (TTM)$-0.41

10-Day Avg Trading Volume2.01M

EPS Excl Extra (TTM)$-0.41

Revenue Growth (5Y)23.00%

EPS (Annual)$-0.39

ROI (Annual)-17.00%

Gross Margin (Annual)74.24%

Net Profit Margin (5Y Avg)-97.06%

Cash / Share (Quarterly)$2.16

Revenue Growth QoQ (YoY)21.53%

ROA (Last FY)-11.60%

Revenue Growth TTM (YoY)50.13%

EBITD / Share (TTM)$-0.33

ROE (5Y Avg)-51.27%

Operating Margin (TTM)-19.86%

Cash Flow / Share (Annual)$-0.32

P/B Ratio27.49x

P/B Ratio (Quarterly)24.02x

Net Income / Employee (Annual)$-95,400

EV / Revenue (TTM)13.29x

Net Interest Coverage (TTM)-24.47x

ROA (TTM)-11.88%

EPS Incl Extra (Annual)$-0.39

Current Ratio (Annual)3.34x

Quick Ratio (Quarterly)4.51x

3-Month Avg Trading Volume2.55M

52-Week Price Return96.54%

Revenue / Employee (TTM)$493,700

Tangible BV / Share (Quarterly)$0.89

P/S Ratio (Annual)14.19x

Asset Turnover (Annual)0.54x

52-Week High$26.16

Operating Margin (5Y Avg)-97.65%

EPS Excl Extra (Annual)$-0.39

CapEx CAGR (5Y)-30.91%

Tangible BV CAGR (5Y)-21.61%

26-Week Price Return61.00%

Quick Ratio (Annual)3.10x

13-Week Price Return84.21%

Total Debt / Equity (Annual)0.60x

Current Ratio (Quarterly)4.79x

Enterprise Value$4.09B

Revenue / Share Growth (5Y)19.47%

Asset Turnover (TTM)0.57x

Book Value / Share Growth (5Y)-23.42%

Revenue / Employee (Annual)$443,900

Inventory Turnover (Annual)7.82x

Pretax Margin (Annual)-21.47%

Cash / Share (Annual)$1.48

3-Month Return Std Dev67.16%

Gross Margin (5Y Avg)65.28%

Net Income / Employee (TTM)$-102,300

ROE (Last FY)-27.19%

Net Interest Coverage (Annual)-21.87x

EPS Basic Excl Extra (Annual)$-0.39

Receivables Turnover (TTM)6.57x

Total Debt / Equity (Quarterly)2.34x

EPS Incl Extra (TTM)$-0.41

Receivables Turnover (Annual)6.01x

ROI (TTM)-16.90%

P/S Ratio (TTM)12.75x

Pretax Margin (5Y Avg)-97.09%

Revenue / Share (Annual)$1.83

Tangible BV / Share (Annual)$1.41

Price vs S&P 500 (52W)78.23%

Year-to-Date Return57.33%

5-Day Price Return4.03%

EPS Normalized (Annual)$-0.39

ROA (5Y Avg)-24.21%

Net Profit Margin (Annual)-21.48%

Month-to-Date Return13.20%

Cash Flow / Share (TTM)$-1.21

EBITD / Share (Annual)$-0.30

Operating Margin (Annual)-20.62%

LT Debt / Equity (Annual)0.58x

ROI (5Y Avg)-38.64%

LT Debt / Equity (Quarterly)2.34x

EPS Basic Excl Extra (TTM)$-0.41

P/TBV (Quarterly)24.17x

P/B Ratio (Annual)11.33x

Inventory Turnover (TTM)7.96x

Pretax Margin (TTM)-20.77%

Book Value / Share (Annual)$1.42

Price vs S&P 500 (13W)81.42%

Beta2.13x

P/FCF (Annual)20.23x

Revenue / Share (TTM)$1.93

ROE (TTM)-32.64%

52-Week Low$12.00

vGradeD

gGradeB

mGradeA

vgmGradeB

ADPT Earnings Surprise History

Q2 25-0.17est. -0.24

Q3 250.06est. -0.14

Q4 25-0.09est. -0.18

Q1 26-0.13est. -0.16

Q2 26-0.25est. -0.13

ADPT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.21

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Adaptive Biotechnologies Corporation Common Stock

Adaptive Biotechnologies develops diagnostic tests that leverage the adaptive immune system to detect and monitor cancer. The company's flagship product, clonoSEQ, is FDA-authorized for minimal residual disease monitoring in patients with multiple myeloma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The test is also available as a CLIA-validated service for other lymphoid malignancies, including diffuse large B-cell lymphoma.